Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 71

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 71
---
;            |

| ● | the commencement of litigation; |

<div align='center'>46</div>

| ● | actual or anticipated changes         
 in estimates as to financial results; |

| ● | announcement or expectation      
 of additional financing efforts; |

| ● | sales of our Ordinary Shares               
 by us, our insiders or other shareholders; |

| ● | expiration of market standoff 
 or lock-up agreements;        |

| ● | variations in our financial                                           
 results or those of companies that are perceived to be similar to us; |

| ● | changes in estimates or                                                
 recommendations by securities analysts, if any, that cover our shares; |

| ● | changes in the structure        
 of health care payment systems; |

| ● | market conditions in the 
 medical device sectors;  |

| ● | the seasonality of our 
 business;              |

| ● | an increase in the rate                                               
 of returns of our GelrinC implants or an increase in warranty claims; |

| ● | the impact of any resurgence                                              
 of COVID-19 or other pandemics on the performance of elective procedures; |

| ● | general economic, industry 
 and market conditions; and |

| ● | the other factors described 
 in this “Risk Factors.”     |

In recent years, the stock
market in general, and the market for medical device companies in particular, has experienced significant price and volume fluctuations
that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing
those price and volume fluctuations. Further, the stock market in general has been highly volatile due to recent geopolitical events
across the world. Broad market and industry factors may seriously affect the market price of our Ordinary Shares, regardless of our actual
operating performance. These fluctuations may be even more pronounced in the trading market for our shares shortly following this offering.
Following periods of such volatility in the market price of a company’s securities, securities class action litigation has often
been brought against that company. Because of the potential volatility of our share price, we may become the target of securities litigation
in the future. Securities litigation could result in substantial costs and divert management’s attention and resources from our
business.

Certain recent initial public offerings of companies with public floats comparable to the anticipated public float of Regentis have experienced extreme volatility that was seemingly unrelated to the underlying performance of the respective company. We may experience similar volatility, which may make it difficult for prospective investors to assess the value of our Ordinary Shares.

Our Ordinary Shares may be